Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07737795) titled 'Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer' on July 27.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: University of Oklahoma

Condition: Endometrial Cancer

Intervention: Drug: OK-1 & Paclitaxel

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: August 2026

Target Sample Size: 66

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07737795

Disclaimer: Curated by HT ...